Investigation Report on Clopidogrel in China, 2018-2022

  • ID: 4587241
  • Report
  • Region: China
  • 30 pages
  • China Research & Intelligence
1 of 5

The researcher predicts that with the rising aging population, the change of lifestyle and the increasing incidence of cerebral stroke, myocardial infarction and peripheral arterial thromboembolism, the demand for Clopidogrel in the Chinese market will continue to increase.

Clopidogrel is a milestone drug in antithrombotic and antiplatelet aggregation. It was approved to be sold on the market by the FDA in 1997. The drug was jointly researched and developed by Bristol-Myers Squibb and Sanofi. Prior to the patent expiration in 2012, Plavix was ranked after Lipitor for many years and was the second best-selling drug in the world. After the patent expired, a global wave of biosimilar boomed.

Clopidogrel was developed early and marketed in China. In 2000, the Clopidogrel of Shenzhen Salubris Pharmaceuticals was first approved for registration under the trade name “Taijia”. In Sept. 2000, the Clopidogrel of Sanofi-Aventis and Bristol-Myers Squibb was granted administrative protection in China. In 2001, Sanofi-Aventis's Clopidogrel was approved to be sold in China under the trade name "Plavix". For years, Clopidogrel has been ranking first in China's antithrombotic drug market, with sales revenue exceeding CNY 2 billion in 2017.

According to the the market research, Clopidogrel in the Chinese market is dominated by four companies, namely, Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Trade Name: Plavix), Shenzhen Salubris Pharmaceutical Co., Ltd. (Trade Name: Taijia), Lepu Pharmaceutical Co., Ltd. (Trade Name: Shuai Tai) and Sanofi (Trade Name: Plavix). According to the sales in 2017, Sanofi (Hangzhou) secured a market share of 52%, ranking first in the Chinese market for a long time.

The researcher predicts that with the rising aging population, the change of lifestyle and the increasing incidence of cerebral stroke, myocardial infarction and peripheral arterial thromboembolism, the demand for Clopidogrel in the Chinese market will continue to increase.

Topics Covered:

  • Development History of Clopidogrel in Chinese Market
  • Development Environment of Clopidogrel in China
  • Sales of Clopidogrel in China
  • Major Clopidogrel Manufacturers in Chinese Market
  • Sale Price of Clopidogrel in Chinese Market
  • Prospects of Chinese Clopidogrel Market, 2018-2022
READ MORE
Note: Product cover images may vary from those shown
2 of 5

1 Relevant Concepts of Clopidogrel
1.1 Indication
1.2 Development History of Clopidogrel in China

2 Market Overview of Clopidogrel in China
2.1 Patents and Government Approval on Clopidogrel
2.2 Major Manufacturers
2.3 Market Size

3 Investigation of Clopidogrel's Sales in China, 2013-2017
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value in Different Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume in Different Regions

4 Market Share of Clopidogrel Manufacturers in China, 2013-2017
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Clopidogrel in Different Dosage Forms, 2013-2017
5.1 Market Share of Clopidogrel in Different Dosage Forms by Sales Value
5.2 Market Share of Clopidogrel in Different Dosage Forms by Sales Volume

6 Reference Sale Price of Clopidogrel in Chinese Market, 2017-2018
6.1 Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Product Trade Name: Plavix)
6.2 Shenzhen Salubris Pharmaceuticals Co., Ltd. (Product Trade Name: Taijia)
6.3 Lepu Pharmaceuticals Co., Ltd. (Product Trade Name: Shuaitai)
6.4 Sanofi (Product Trade Name: Plavix)

7 Major Clopidogrel Manufacturers in Chinese Market, 2013-2017
7.1 Sanofi Pharmaceutical Co., Ltd.
7.1.1 Enterprise Profile
7.1.2 Sales of Clopidogrel of Sanofi (Hangzhou) in China
7.2 Shenzhen Salubris Pharmaceuticals Co., Ltd.
7.3 Lepu Pharmaceuticals Co., Ltd.
7.4 Sanofi

8 Prospects of Chinese Clopidogrel Market, 2018-2022
8.1 Forecast on Market Size
8.2 Forecast on Development Trend

Table of Charts
Chart Chinese Government Approval on Clopidogrel
Chart Sales of Clopidogrel in China, 2013-2017
Chart Sales Value of Clopidogrel in China, 2013-2017
Chart Sales Value of Clopidogrel in Parts of China, 2013-2017
Chart Sales Volume of Clopidogrel in China, 2013-2017
Chart Sales Volume of Clopidogrel in Parts of China, 2013-2017
Chart Sales Value and Market Share of Clopidogrel of Sanofi (Hangzhou), 2013-2017
Chart Sales Value and Market Share of Clopidogrel of Shenzhen Salubris, 2013-2017
Chart Sales Value and Market Share of Clopidogrel Tablets in China, 2013-2017
Chart Sales Volume and Market Share of Clopidogrel Tablets in China, 2013-2017
Chart Sale Price of Clopidogrel of Sanofi (Hangzhou) in Several Chinese Cities, 2017
Chart Sale Price of Clopidogrel of Shenzhen Salubris in Several Chinese Cities, 2017
Chart Forecast on Clopidogrel's Sales in China, 2018-2022

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Lepu Pharmaceuticals Co., Ltd.
  • Sanofi
  • Sanofi Pharmaceutical Co., Ltd.
  • Shenzhen Salubris Pharmaceuticals Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll